All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

In recent decades, Acetylcholinesterase (AChE) has become a major interest in Alzheimer's disease (AD) research. AD, a neural degenerative disorder, is characterized by accumulation of extracellular and vascular amyloid in the brain \[[@pone.0211935.ref001]--[@pone.0211935.ref003]\]. In brief, inhibitors of AChE enhance the acetylcholine (ACh) level and also sustain the duration of neurotransmitter action. AChE is also proposed to play an important role in Aβ-aggregation during plaque formation \[[@pone.0211935.ref004]\]. Research from the last decades explain the pathology of AD; in which, one strategy suggested that a decrease in AChE production at synaptic junction highly correlated with the onset of AD progression \[[@pone.0211935.ref005]--[@pone.0211935.ref007]\]. Estimations regarding AD showed that there are 35.6 million people with dementia worldwide as of 2010, and every 20 years this number is projected to double reaching 65.7 million in 2030 and 115.4 million in 2050 \[[@pone.0211935.ref008]\]. Several AChE inhibitors such as galantamine, donepezil, tacrine and rivastigmine are available for AD therapy, known to inhibit AChE, however, they are effective to treat mild to moderate AD only \[[@pone.0211935.ref009]\]. These drugs showed a non-selective profile along with limited efficacy, adverse cholinergic side effects in the periphery, poor bioavailability, and hepatotoxicity, though around 40--70% patients benefit from AChE inhibitors \[[@pone.0211935.ref010]\].

The crystal structure of AChE resolved by X-ray crystallographic technique contains two main binding sites, including the catalytic active site (CAS), which is formed by serine, histidine and glutamate, and the peripheral anionic site (PAS) connected by a deep, hydrophobic gorge \[[@pone.0211935.ref011]\]. Among the drugs targeting AChE, donepezil and other bifunctional inhibitors also may span the AChE gorge \[[@pone.0211935.ref012]\]. The detailed interactions analysis suggested that this drug has an exclusive orientation, extending from the CAS (bottom near Trp86) to the PAS (top near Trp286), along the active-site gorge. These studies established a structural baseline for improved inhibitor design of next-generation derivatives \[[@pone.0211935.ref013]--[@pone.0211935.ref015]\].

The use of metals in drug design has recently gained interest by the success of the anticancer drug, cisplatin \[[@pone.0211935.ref016],[@pone.0211935.ref017]\]. Recently, drugs based on metal complexes are used as therapeutic agents (*e*.*g*., Pt, Au, and Ru) in the treatment of malignant diseases, including several types of cancers \[[@pone.0211935.ref018],[@pone.0211935.ref019]\]. Therefore, in this study, a main focus was to design metal based analogues of donepezil by adding Cu^2+^ as a metal to improve its activity and efficacy. Theoretical work is conducted and validated using density functional theory (DFT), molecular docking, and molecular dynamics (MD) simulation studies. Moreover, some other metals (such as Fe, Co, Zn and Ni) are also incorporated with donepezil similar to the best copper based derivative.

Methods {#sec002}
=======

Designing and optimization of ligands {#sec003}
-------------------------------------

The molecules were drawn on the BIOVIA Drawer. 3D structures were then generated by fully optimizing with DFT, employing Becke's exchange functional combining Lee, Yang, and Parr's (LYP) correlation functional \[[@pone.0211935.ref020],[@pone.0211935.ref021]\]. As all designed compounds were modified with metal atoms, the SDD (Stuttgart/Dresden) basis set was used \[[@pone.0211935.ref022]\]. After optimization, subsequent vibrational frequency calculations were performed to confirm that the stationary points corresponded to minima on the potential energy surface. Electronic energies, enthalpies, Gibbs free energies, dipole moments, and partial charge analysis of each compound were also investigated. Hardness and softness of all compounds were determined from the energies (ε) of frontier HOMOs and LUMOs. Considering the Parr and Pearson interpretation \[[@pone.0211935.ref023]\] of DFT and Koopmans theorem \[[@pone.0211935.ref024]\], hardness (η), and softness (S) of the drugs were calculated according to the following equation.

![](pone.0211935.e001.jpg){#pone.0211935.e001g}

η

=

(

ε

H

O

M

O

−

ε

L

U

M

O

)

2

![](pone.0211935.e002.jpg){#pone.0211935.e002g}

s

=

1

η

Molecular docking analysis {#sec004}
--------------------------

The three-dimensional crystal structure of recombinant human AChE (PDB ID: **4ey7**) was retrieved in pdb format from the protein data bank \[[@pone.0211935.ref025]\]. The model was then subjected to energy minimization using the steepest descent and conjugate gradient technique to eliminate bad contacts of protein atoms. Computations were carried out *in vacuo* with the GROMOS 96 43B1 parameters set, with implementation using the Swiss-PDB Viewer. For docking analysis, AutodockVina was employed and AutoDock Tools (ADT) of the MGL software package was used to convert pdb into a pdbqt format to input protein and ligands. The size of grid box in AutoDockVina was kept at 58.81735, 61.2066, and 72.8273 respectively for X, Y, Z. AutodockVina was implemented through the shell script provided by AutoDockVina developers. The binding affinity of ligand was observed by kcal/mole as a unit for a negative score \[[@pone.0211935.ref026]\].

Molecular dynamics simulation {#sec005}
-----------------------------

To validate the predictions from docking studies, MD simulation was performed using the NAMD \[[@pone.0211935.ref027]\] software, version 2.9. In this study, the CHARMM force field \[[@pone.0211935.ref028]\] was utilized, as it is widely applied to describe the macromolecular system. The Transferable Intermolecular Potential3 Points (TIP3P) water model was used by adding Cl^-^ and/or Na^+^ ions, where the total solvent molecules, 20109, have a density of 1.012 gm/cm^3^. A periodic boundary condition was employed to perform the simulation, where the box size used was 82.4×85.0×98.8Å^3^. Following the steepest descent energy minimization, equilibration of 100 steps was performed by NPT ensemble. Using Langevin Dynamics for constant temperature, full-system periodic electrostatics were maintained using the Particle Mesh Ewald (PME)\[[@pone.0211935.ref029]\]. Consistently Nose-Hoover Langevin piston \[[@pone.0211935.ref030],[@pone.0211935.ref031]\] was used for constant pressure dynamics and SHAKE was used to keep all bonds involving hydrogen atoms at their equilibrium values. Finally, the full system was subjected to MD production run at 300 K for 25 ns in the NVT ensemble. The MD trajectories were saved every 50 ps for analysis.

Ensemble based molecular docking {#sec006}
--------------------------------

To further clarify the results of docking predictions, we used an ensemble based docking method, where two different approaches were employed to obtain different conformations from AChE. In the first approach, different crystallographic conformations of AChE were retrieved from protein data bank, PDB IDs: 1b41, 1f8u, 1vzj, 2x8b, 3lii, 4bdt, 4ey6, 4ey8, 4moe, 4pqe, 5foq, 5fpq, 5hf5, 5hf6, 5hf8, 5hf9, 5hfa. In the second approach, conformers were taken from the 25 ns MD simulation (PDB ID: **4ey7**) at every 1 ns of the 25 ns MD simulation. Against these conformers, the compounds donepezil, D8, D9 and D10 were subjected for docking using the same protocol discussed above in the methods section.

Pharmacokinetic parameters study {#sec007}
--------------------------------

To check the pharmacokinetic parameters and toxicity of the modified compounds and parent compound, the admetSAR server was utilized. We have utilized the admetSAR online database to evaluate the pharmacokinetics parameters related to drug absorption, metabolism and toxicity of the parent drug and its designed analogues \[[@pone.0211935.ref032]\]. Using structure similarity search methods, admetSAR predicts the latest and most comprehensive manually curated data for diverse chemicals associated with known ADME/T profiles.

For ADMET analysis, the admetSAR program was used in which 96,000 unique compounds with 45 kinds of ADMET-associated properties, proteins, species, or organisms have been carefully curated from a large number of diverse literatures. Although it is quite difficult to verify all of these compounds and to know whether this program included metal-based drugs or not, we used well known Pt-based cisplatin and carboplatin as well as metal-based drugs approved in the FDA and in clinical trials as test candidates to verify our metal-based donepezil drugs.

Results and discussions {#sec008}
=======================

Strategies and optimization of designed analogue {#sec009}
------------------------------------------------

The new analogues of donepezil used in this study were designed according to the structural properties of the active site of AChE. As described above, among the two binding sites of AChE, the peripheral anionic site plays a significant role in ligand reorganization and allosteric activators \[[@pone.0211935.ref033],[@pone.0211935.ref034]\]. The stabilization of the substrates binding on this site is largely π-cation interaction, while choline ester substrate specificity is mediated partly by Phe295 and Phe297 \[[@pone.0211935.ref035]\]. From detailed analysis of enzyme-inhibitor complexes, it appeared that the indole ring of Trp286 was involved in direct interaction with several inhibitors, showing a number of interaction modes including stacking, aromatic-aromatic, and π-cation, according to the nature of the ligands \[[@pone.0211935.ref036]--[@pone.0211935.ref038]\]. Furthermore, the active site of AChE forms electrostatic interactions with the substrates, as all of the amino acids were distributed with a large dipole moment. Information from the above studies, therefore, motivated us to design new analogues of donepezil, by increasing their electronegativity and the non-covalent interaction capacity between the aromatic rings.

As shown in **[Fig 1](#pone.0211935.g001){ref-type="fig"}**, ten analogues (D1-D10) were designed by modifying donepezil (D), which may react with \[CuCl~2~(H~2~O)~2~\] affording the probable mononuclear copper complexes \[Cu(D)n(H~2~O)~2~\]. There were also several additional modifications in D2-D10. D2-D5 were modified by the addition of F (D2), Cl (D3), Br (D4), and I (D5) atoms in the 2,3-dihydroindene ring portion, respectively. In contrast, D6 was designed by corresponding with D5 while modifications occurred only in the attached benzene ring, *i*.*e*., benzene ring with CF~3~ group. In D7 and D8, attached benzene ring of the parent structure was replaced by naphthalene and anthracene rings, respectively, with no halogen modification; however, replacement of H with F and Cl atoms at the 2,3-dihydroindene ring portion of D8 results new analogues D9 and D10, respectively.

![The design of new analogues based on the potent, first generation molecule, donepezil.\
Here, D1 was designed from donepezil, while others (D2 to D10) are based on the basic structure of D1.](pone.0211935.g001){#pone.0211935.g001}

As the conformational features of a molecule critically influences its physical and chemical properties, all of designed compounds along with parent compound, donepezil, were subjected to full geometry optimization using DFT. [Table 1](#pone.0211935.t001){ref-type="table"} illustrates the stoichiometry, electronic energy, enthalpy, Gibbs free energy and dipole moment of the compounds and the optimized structures are depicted in **[Fig 2](#pone.0211935.g002){ref-type="fig"}**.

![Most stable optimized structures of all designed analogues along with their parent molecule, donepezil.\
All analogues were optimized in the gas phase at B3LYP/SDD level in Gaussian 09.](pone.0211935.g002){#pone.0211935.g002}

10.1371/journal.pone.0211935.t001

###### The stoichiometry, electronic energy, enthalpy, Gibbs free energy (in Hartree), and dipole moment (Debye) of donepezil and its designed analogues.

![](pone.0211935.t001){#pone.0211935.t001g}

  -----------------------------------------------------------------------------------------------------------
  Name        Stoichiometry               Electronic Energy   Enthalpy   Gibbs Free Energy   Dipole Moment\
                                                                                             (Debye)
  ----------- --------------------------- ------------------- ---------- ------------------- ----------------
  Donepezil   C~24~H~29~NO~3~             -1204.88            -1204.88   -1204.97            2.575

  D1          C~22~H~27~CuNO~5~(2)        -1482.22            -1482.22   -1482.31            11.349

  D2          C~22~H~26~CuFNO~5~(2)       -1581.48            -1581.48   -1581.57            13.547

  D3          C~22~H~26~ClCuNO~5~(2)      -1941.80            -1941.80   -1941.90            13.328

  D4          C~22~H~26~BrCuNO~5~(2)      -1495.00            -1495.00   -1495.10            13.299

  D5          C~22~H~26~CuINO~5~(2)       -1493.04            -1493.03   -1493.13            13.070

  D6          C~23~H~25~CuF~3~INO~5~(2)   -1830.08            -1830.08   -1830.19            12.787

  D7          C~26~H~29~CuNO~5~(2)        -1635.79            -1635.79   -1635.89            11.360

  D8          C~30~H~31~CuNO~5~(2)        -1789.35            -1789.35   -1789.45            11.821

  D9          C~30~H~30~CuFNO~5~(2)       -1888.61            -1888.61   -1888.71            13.596

  D10         C~30~H~30~ClCuNO~5~(2)      -2248.93            -2248.93   -2249.04            13.346
  -----------------------------------------------------------------------------------------------------------

According to the **[Table 1](#pone.0211935.t001){ref-type="table"}**, it is clear that modifications on donepezil significantly influenced the structural properties of the compounds in terms of energy, partial charge distribution, and dipole moment. The highest energy, enthalpy, and Gibbs free energy was observed for D10, while D9 showed the highest dipole moment of 13.596 Debye, representing high polarity in nature. It is important to note that incorporation of the--CF~3~ group in D5 significantly reduced the dipole moment, as can be seen in D6; however, D1, D7, D8 showed low dipole moments of 13.596 Debye due to the lack of halogens.

Analysis of frontier molecular orbitals {#sec010}
---------------------------------------

The frontier molecular orbitals are the most important orbitals in a molecule and they are considered to characterize the chemical reactivity and kinetic stability. These frontier molecular orbitals are known as the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO). **[Table 2](#pone.0211935.t002){ref-type="table"}** represents the values of orbital energies, along with the two global chemical descriptors, hardness and softness, which are also calculated for all compounds. The highest softness was observed for D8. D8 also showed the lowest HOMO-LUMO gap and hardness, indicating that the molecule is more reactive than other compounds, according to Pearson *et al*. \[[@pone.0211935.ref039],[@pone.0211935.ref040]\]. In **[Fig 3](#pone.0211935.g003){ref-type="fig"}**, the HOMO plot of compound D9 showed that the electrons were localized on the upper part of the piperidine ring, while the LUMO plot showed that the electrons were localized at modified Cu regions only.

![Molecular orbital distribution plots of HOMO and LUMO in the ground state of D9 analogue and donepezil at DFT/SDD level of theory in the gas phase.](pone.0211935.g003){#pone.0211935.g003}

10.1371/journal.pone.0211935.t002

###### Energy of HOMOs, LUMO, gap, hardness and softness (all units are in Hartree) of the donepezil and its designed analogues.

![](pone.0211935.t002){#pone.0211935.t002g}

  -----------------------------------------------------------------------------------------------
  Molecules   *ε*~*HOMO-1*~   *ε*~*HOMO*~   *ε*~*LUMO*~   *Gap*     *η* (Hardness)   *S*\
                                                                                     (Softness)
  ----------- --------------- ------------- ------------- --------- ---------------- ------------
  Donepezil   -0.23073        -0.21374      -0.04412      0.16962   0.08481          11.7911

  D1          -0.19606        -0.18662      -0.05973      0.12689   0.063445         15.7617

  D2          -0.19405        -0.19230      -0.06407      0.12823   0.064115         15.5970

  D3          -0.19398        -0.19335      -0.06368      0.12967   0.064835         15.4238

  D4          -0.19498        -0.19336      -0.06365      0.12971   0.064855         15.4190

  D5          -0.19536        -0.19256      -0.06432      0.12824   0.06412          15.5958

  D6          -0.20900        -0.19490      -0.06797      0.12693   0.063465         15.7567

  D7          -0.19577        -0.18635      -0.05953      0.12682   0.06341          15.7703

  D8          -0.19064        -0.18695      -0.06296      0.12399   0.061995         16.1303

  D9          -0.19382        -019036       -0.06383      0.12653   0.063265         15.8065

  D10         -0.19344        -0.19093      -0.06358      0.12735   0.063675         15.70475
  -----------------------------------------------------------------------------------------------

Molecular docking analysis {#sec011}
--------------------------

In order to check the binding modes of modified compounds, molecular docking simulations by Autodock Vina were performed. Molecular docking is one of the most common methods used in structure based drug design to analyze the interaction between a small molecule and a protein at the atomic level. Prior to docking, the crystal pose of donepezil was re-docked into the binding site of AChE with specific docking parameters and scoring functions, to check whether the docking software is reliable for the system. The conformation having the lowest negative score was then compared with the crystal pose. The value of the root mean square deviation (RMSD) of the docked conformation with respect to experimental conformation was 1.9659 Å (**[Fig 4](#pone.0211935.g004){ref-type="fig"}**), signifying the reliability of the docking protocol, as the threshold of reliability is 2.0 Å for a good docking protocol.

![Predicted pose from molecular docking by Autodock Vina.\
Here, the stick representations of ligands denote the superimposed view of docked (pink) and co-crystallized ligand (green).](pone.0211935.g004){#pone.0211935.g004}

Afterward, all designed analogues were docked into the same binding site pocket of AChE, using similar optimized docking conditions. The outcomes of the docking analysis showed that all compounds, along with the parent compound, obtain binding affinities ranging from -10.2 to -14.9 kcal/mol. As shown in **[Table 3](#pone.0211935.t003){ref-type="table"}**, D4, D5, D6 showed low binding affinities compared to parent compound, donepezil, while D1 exhibited high binding affinity. These results indicated that modification of Cu along with a water molecule increased the binding affinity, while addition of halogen groups like Br, I, and CF~3~ made some fluctuations in binding affinities; however, modification with naphthalene and anthracene rings increased the binding affinity. As shown with D7 and D8, obtained docking affinities of -13.9 and -14.8 kcal/mol were determined, respectively. The highest binding affinity was observed for the D9 compound. According to the post docking analysis, it was revealed that all compounds, except D6, showed π-alkyl interactions with Tyr337 and Phe338 residues of the PAS in the active site of the enzyme. D6 is positioned to form stabilizing π-alkyl interactions with Trp286, Tyr337, Tyr341 residues. Furthermore, it was also observed that modifications of donepezil increased the π-π interactions with the residues of the active site, while increasing their polarity resulted in the formation of hydrogen bonding interactions. The highest H-bonds were obtained for the D10 compound, forming with Gln291, Ser293, Phe295, Arg296 residues. In contrast, D7, D8, and D9 formed three H-bonds with Tyr72 and Phe295 residues. D8 and D9 showed similar binding conformations, despite having different bonding distances. Along with Trp286, D8, D9, and D10 displayed the maximum π- π interactions with the Trp86 residue denoting the tight binding with the activesite. Reports suggest that Trp286 is considered as the principal component of the PAS, responsible for the accessibility of small molecules to the active site and also in the allosterism, while aromatic interactions with the Trp286 residue modulates the inhibition constants for some AChE inhibitors \[[@pone.0211935.ref041],[@pone.0211935.ref042]\]. As the D9 compound showed the highest binding affinity (**[Fig 5](#pone.0211935.g005){ref-type="fig"}**), it was subjected for subsequent MD, along with donepezil, to investigate the dynamic stability of the AChE-inhibitor complex, and also, to ensure the rationality of the sampling strategy.

![Predicted pose from the docking analysis showed the binding orientation map of important amino acids for analogue D9, showing hydrogen bond interaction (green color), including π--π stacking (pink color).](pone.0211935.g005){#pone.0211935.g005}

10.1371/journal.pone.0211935.t003

###### Binding affinity (kcal/mol) and nonbonding interactions of donepezil and its designed analogues.

![](pone.0211935.t003){#pone.0211935.t003g}

  ------------------------------------------------------------------------------------------------------------------------------
  Compound         Binding Affinity\   Hydrophobic   Hydrogen Bond                                                       
                   (kcal/mol)                                                                                            
  ---------------- ------------------- ------------- --------------- -------- ------- -------------- -------- ---------- -------
  Donepezil        -11.9               Pi-Alkyl      TYR337          X        5.344                                      

  PHE338           X                   4.865                                                                             

  TYR341           X                   5.342                                                                             

  Pi-Pi Stacked    TRP286              X1            4.175                                                               

  TYR341           X1                  5.303                                                                             

  TRP86            X                   3.732                                                                             

  TRP86            X                   4.373                                                                             

  TRP286           X1                  5.466                                                                             

  D1               -12.3               Pi-Alky       TYR337          X        5.084   Conventional   PHE295   H...O      1.917

  PHE338           X                   5.194                                                                             

  TYR341           X                   4.847                                                                             

  Pi-Pi Stacked    TRP286              X1            4.039                                                               

  TYR341           X1                  5.124                                                                             

  TRP86            X                   3.731                                                                             

  TRP86            X                   4.367                                                                             

  TRP286           X1                  5.213                                                                             

  D2               -12.7               Pi-Alkyl      TYR337          X        4.703   Conventional   TYR124   H...O      2.739

  PHE338           X                   5.171                                                                             

  TYR341           X                   4.613                                                                             

  Pi-Pi Stacked    TRP286              X1            4.068                                                               

  TYR341           X1                  5.302                                                                             

  TRP86            X                   4.025                                                                             

  TRP86            X                   4.430                                                                             

  TRP286           X1                  5.355                                                                             

  HIS447           X                   5.353                                                                             

  Pi-Sigma         TYR341              H...X         2.589                                                               

  D3               -12.4               Pi-Alkyl      TYR337          X        4.770   Conventional   PHE295   H...O      1.944

  PHE338           X                   5.276                                                                             

  TYR341           X                   4.497                                                                             

  Pi-Pi Stacked    TRP286              X1            4.017                                                               

  TYR341           X1                  5.387                                                                             

  TRP86            X                   3.954                                                                             

  TRP86            X                   4.301                                                                             

  TRP286           X1                  5.244                                                                             

  HIS447           X                   5.369                                                                             

  D4               -11.2               Pi-Alkyl      TYR337          X        4.457   Conventional   PHE295   H...O      1.905

  PHE338           X                   5.025                                                                             

  TYR341           X                   4.665                                                                             

  Pi-Pi Stacked    TRP286              X1            4.202                                                               

  TYR341           X1                  5.099                                                                             

  TRP86            X                   3.751                                                                             

  TRP86            X                   4.341                                                                             

  TRP286           X1                  5.541                                                                             

  HIS447           X                   5.864                                                                             

  D5               -10.2               Pi-Alkyl      TYR337          X        4.301   Conventional   PHE295   H...O      2.021

  PHE338           X                   4.988                                                                             

  TYR341           X                   4.797                                                                             

  Pi-Pi Stacked    TRP286              X1            4.367                                                               

  TYR341           X1                  5.015                                                                             

  TRP86            X                   3.782                                                                             

  TRP86            X                   4.410                                                                             

  D6               -10.8               Pi-Alkyl      TRP286          X        4.113   Conventional   LEU289   H...O      1.922

  TYR337           X                   4.138                                                                             

  TYR341           X                   4.894                                                                             

  Pi-Pi T-Shaped   TYR337              X             5.922                                                               

  TYR341           X                   4.780                                                                             

  D7               -13.9               Pi-Alkyl      TYR337          X2       5.408   Conventional   TYR72    C--H...O   2.717

  PHE338           X2                  4.826                                                                             

  TYR72            C--H...O            2.745                                                                             

  PHE295           C--H...O            2.497                                                                             

  Pi-Pi Stacked    TRP286              X1            4.071                                                               

  TRP86            X2                  4.142                                                                             

  TRP86            X2                  3.830                                                                             

  TRP86            X2                  4.453                                                                             

  TRP86            X2                  4.363                                                                             

  TRP286           X1                  4.951                                                                             

  Pi-Sigma         TYR341              H...X2        2.735                                                               

  D8               -14.8               Pi-Alkyl      TYR337          X3       5.452   Conventional   TYR72    H...O      2.285

  PHE338           X3                  4.739                                                                             

  Pi-Pi Stacked    TRP286              X1            4.119                                                               

  TRP86            X3                  4.501                                                                             

  TYR72            H...O               2.731                                                                             

  PHE295           H...O               2.486                                                                             

  TRP86            X3                  3.884                                                                             

  TRP86            X3                  4.154                                                                             

  TRP86            X3                  4.683                                                                             

  TRP86            X3                  4.977                                                                             

  TRP286           X1                  5.003                                                                             

  Pi-Pi T-Shaped   TYR124              X3            5.784                                                               

  Pi-Sigma         TYR341              H...X3        2.62                                                                

  D9               -14.9               Pi-Alkyl      TYR337          X3       5.367   Conventional   TYR72    H...O      3.069

  TYR72            H...O               2.741                                                                             

  PHE295           H...O               2.755                                                                             

  PHE338           X3                  4.850                                                                             

  Pi-Pi Stacked    TRP286              X1            4.097                                                               

  TRP86            X3                  4.454                                                                             

  TRP86            X3                  3.880                                                                             

  TRP86            X3                  4.144                                                                             

  TRP86            X3                  4.724                                                                             

  TRP86            X3                  4.926                                                                             

  TRP286           X1                  4.888                                                                             

  Pi-Pi T-Shaped   TYR124              X3            5.809                                                               

  Pi-Sigma         TYR341              H...X3        2.48                                                                

  D10              -14.7               Pi-Alkyl      TYR337          X3       5.292   Conventional   GLN291   H...O      2.412

  PHE338           X3                  5.289                                                                             

  TYR341           X3                  3.914                                                                             

  SER293           H...O               2.380                                                                             

  Pi-Pi Stacked    TRP286              X1            4.282           PHE295   H...O   1.667                              

  ARG296           H...O               2.851                                                                             

  TRP86            X3                  4.576                                                                             

  TRP86            X3                  3.842                                                                             

  TRP86            X3                  3.921                                                                             

  TRP86            X3                  4.109                                                                             

  TRP86            X3                  5.104                                                                             

  TRP286           X1                  5.705                                                                             
  ------------------------------------------------------------------------------------------------------------------------------

Here X, X1, X2, X3 indicates that, X = Benzyl-4-piperidyl, X1 = 2,3-dihydro-1H-inden-1-one, X2 = Naphthalen-1-ylmethyl-4-piperidyl, X3 = Anthracen-9-ylmethyl-4-piperidyl

Furthermore, to understand how D9 showed its binding modes with different metals, different metal atoms such as Fe, Co, Zn and Ni were inserted to the same position of D9 where Cu is present and they are renamed as D9-Fe, D9-Co, D9-Zn and D9-Ni, respectively (**[S1 Fig](#pone.0211935.s005){ref-type="supplementary-material"}**). These analogues were optimized by DFT and the subsequent molecular docking was performed by the same protocol discussed above in the methods section. Afterward, obtained results were represented in **[S1 Table](#pone.0211935.s001){ref-type="supplementary-material"}**. As shown in **[S1 Table](#pone.0211935.s001){ref-type="supplementary-material"}**, D9-Fe, D9-Co, D9-Zn, D9-Ni showed low binding affinities compared to D9. As per the post docking analysis, it is shown that D9-Fe, D9-Co, D9-Zn showed the π-alkyl interactions with Tyr337 and Phe338 residues of the PAS of the active site of the enzyme, like D9, respectively, while the Val294 residue only formed π-alkyl interaction with D9-Ni. In addition, it was revealed that all of the modified D9 compounds, except D9-Ni, showed maximum π-π interactions with Trp286 and Trp86. D9-Ni formed major π-π interaction with Trp286 along with the Tyr341 residue, which was also observed in D9-Co and D9-Zn. Furthermore, D9-Co and D9-Zn formed a hydrogen bond with the Phe295 residue while D9-Fe forms H-bonding with both Phe295 and Tyr72 residue, as like the D9 compound (illustrated in **[S2 Fig](#pone.0211935.s006){ref-type="supplementary-material"}**). From the different metal based study of D9, analysis finally revealed that D9-Cu performs better binding than other candidates.

Molecular dynamics simulations {#sec012}
------------------------------

In order to understand the binding mechanism, structural behavior, and flexibility of compound D9, we performed MD simulations for 25 ns. The complex of donepezil-protein was also subjected to MD simulation as a reference compound. The atomic RMSDs of the Cα atoms for both protein and the ligand of each complex were calculated and plotted in a time dependent manner (**[Fig 6](#pone.0211935.g006){ref-type="fig"})**. **[Fig 6A](#pone.0211935.g006){ref-type="fig"}** demonstrats the behavior of the protein during the simulation; in which, both complexes were observed to achieve equilibrium after 5 ns and fluctuated around 0.5 Å. However, after 20 ns, D9 complex showed lower RMSD and remained afterward. Similar results were also obtained for ligands of each complex, as shown in **[Fig 6B](#pone.0211935.g006){ref-type="fig"}**. As can be seen in the plot, high fluctuation in RMSDs was observed for donepezil, where the high magnitudes were observed at 16 ns to 18 ns. The RMSD results from both protein and ligand indicated that the complexes were stable, suggesting higher stability of D9 in comparison with donepezil.

![The time series of the RMSD of backbone atoms (C, Cα, and N) for a) protein and b) ligand for each docked complex. Here, red and blue lines denote donepezil and D9 complex respectively.](pone.0211935.g006){#pone.0211935.g006}

For better understanding on how D9 and donepezil influence the binding mode with AChE, the structural changes of two complexes were examined by means of root mean square fluctuation (RMSF), radius of gyration, and solvent accessible surface area (SASA) of the protein (**[Fig 7](#pone.0211935.g007){ref-type="fig"}**). **[Fig 7A](#pone.0211935.g007){ref-type="fig"}** represents the total SASA of each protein, in which the D9 compound showed decreased SASA after 15 ns of simulation, demonstrating lower compactness of the protein structure. In contrast, the results from the radius of gyration analysis (**[Fig 7B](#pone.0211935.g007){ref-type="fig"})** described that D9 comparatively produced a higher radius of gyration value than donepezil, denoting loose packing of the protein structure, which eventfully supported the results from the SASA analysis. RMSF values were also calculated from the trajectories, which reflect the flexibility of each residue in the protein\[[@pone.0211935.ref043]\]\[[@pone.0211935.ref043]\]\[[@pone.0211935.ref043]\]\[[@pone.0211935.ref043]\]\[[@pone.0211935.ref043]\]\[[@pone.0211935.ref043]\]\[[@pone.0211935.ref043]\]\[[@pone.0211935.ref043]\]\[[@pone.0211935.ref043]\]\[[@pone.0211935.ref042]\]\[[@pone.0211935.ref041]\]\[[@pone.0211935.ref040]\]\[[@pone.0211935.ref040]\]\[[@pone.0211935.ref040]\]\[[@pone.0211935.ref040]\]\[[@pone.0211935.ref040]\]\[[@pone.0211935.ref039]\]. According to **[Fig 7C](#pone.0211935.g007){ref-type="fig"}**, it was observed that D9 induced flexibility to some residues in the protein. Highest fluctuations were observed in several regions, ranging from 116--125, 280--290, 310--320, 361--370, and 505--515. Finally, the information of hydrogen bonding interactions formed within the protein, and also between the protein and ligand at the catalytic domain, was collected from the trajectories and represented in **[Fig 8A](#pone.0211935.g008){ref-type="fig"}**. Here, the D9 complex showed maximum intramolecular hydrogen bonds in the donepezil complex, demonstrating the stability of the complex. The intermolecular hydrogen bond analysis between the protein and ligand displayed that donepezil and D9 formed hydrogen bonds with the residues of the catalytic domain (**[Fig 8B](#pone.0211935.g008){ref-type="fig"}**). At the initial step, D9 did not show much interaction; however, after 11 ns, it showed several H-bond contacts. Consequently, donepezil revealed no hydrogen bonding in the docking pose, although it detected several contacts during the simulations. As a corollary, all analyses from the MD simulations suggested that D9 is more stable than donepezil and caused little conformational changes of the protein by undergoing little movement during the MD simulations **([Fig 9](#pone.0211935.g009){ref-type="fig"})**.

![The structural changes of protein by means of a) solvent accessible surface area (SASA), b) radius of gyration, and c) root means square fluctuations (RMSF) analysis. Here, red and blue lines denote donepezil and D9 complex, respectively.](pone.0211935.g007){#pone.0211935.g007}

![Total number of hydrogen bonds formed a) within the protein and b) between the protein and ligand in complex state during the simulation. Here, red and blue lines denote donepezil and D9 complex, respectively.](pone.0211935.g008){#pone.0211935.g008}

![Conformational changes of the D9-AChE complex.\
Here, the stick model of the ligand in blue color represents the starting conformation of the complex, while the green color represents the conformation of last step in the 25 ns long MD simulation.](pone.0211935.g009){#pone.0211935.g009}

Ensemble based docking {#sec013}
----------------------

Usually, proteins are flexible macromolecules in nature. However, this property significantly influences ligand binding, especially in molecular reorganization and interactions \[[@pone.0211935.ref044]\]. Compared to the other program, AutoDock Vina is the most popular docking program to determine the binding pose of the ligand, yet suffers from backbone flexibility in receptors. Therefore, ensemble based molecular docking by AutoDock Vina has been introduced in this study to overcome this limitation. The results obtained are represented in **[Table 4](#pone.0211935.t004){ref-type="table"} and [Table 5](#pone.0211935.t005){ref-type="table"}**. **[Table 4](#pone.0211935.t004){ref-type="table"}** and **[Fig 10A](#pone.0211935.g010){ref-type="fig"}** describe the binding affinity of all ligands with different crystallographic conformations of the AChE enzyme. Interestingly, designed compounds showed better results than the standard drug, donepezil. Among these crystal conformers, designed compounds and donepezil produced best docking scores against the 5foq conformer (**[Fig 10A](#pone.0211935.g010){ref-type="fig"})**, and therefore, detailed molecular interactions of this conformer have been investigated and illustrated in **[Table 6](#pone.0211935.t006){ref-type="table"}**. As can be seen in **[Table 6](#pone.0211935.t006){ref-type="table"}**, the D9 compound formed two additional hydrophobic interactions with Tyr341 and Trp286 residues followed by π-alkyl and π-π stacked bonds, and also obtained the highest docking score. In case of D8 compound, additional hydrogen bonds were observed with Ser293 and Trp286 residues, while the polar interactions with Tyr72 and Phe295 were seen to disappear. Similarly, loss of hydrogen bonds was also observed for Gln291, Phe295, and Arg296 residues. All ligands showed better binding affinities against the conformer obtained from MD simulation at 17 ns, as shown in **[Table 5](#pone.0211935.t005){ref-type="table"}** and **[Fig 10B](#pone.0211935.g010){ref-type="fig"}**. Detailed molecular interactions were illustrated in **[Table 6](#pone.0211935.t006){ref-type="table"}** which represents the breakdown of π-alkyl interactions of Tyr341, Tyr337, and Tyr124 residues. Instead, they formed π-π stacking with the ligands. Also, D9 and D10 compounds showed an additional salt bridge with the Asp74 residue followed by π-cation interactions. It is noteworthy to state that the flexibility of AChE is the major determinant of the binding affinity of the ligands, as evident from ensemble-based docking. π-π stacking with the residues of Trp86, Tyr337, Tyr341, Tyr124, and Trp286 showed a major contribution for strong drug binding and activity. Our study suggested that protein flexibility can give rise to differences in binding affinity and binding interaction of a drug with its target protein.

![Binding affinities of designed ligands and standard inhibitor, obtained from ensemble based docking analysis.\
Here, binding affinities of D8, D9, D10, and donepezil against multiple AChE conformers from a) protein data bank and b) 25 ns MD simulation.](pone.0211935.g010){#pone.0211935.g010}

10.1371/journal.pone.0211935.t004

###### Ensemble based docking against all crystal structures of AChE.

![](pone.0211935.t004){#pone.0211935.t004g}

  -------------------------------------------------------------------------
  PDB ID   Resolution (Å)   Sequence\   Donepezil   D8      D9      D10
                            Positions                               
  -------- ---------------- ----------- ----------- ------- ------- -------
  1b41     2.76             36--574     -8.6        -11.2   -11.6   -11.6

  1f8u     2.90             32--614     -8.8        -11.3   -11.6   -11.7

  1vzj     2.35             575--614    -6          -7.3    -7.5    -7.5

  2x8b     2.95             32--614     -9          -11.2   -11.6   -11.4

  3lii     3.20             35--574     -9.1        -12     -11.9   -11.8

  4bdt     3.10             32--614     -8.5        -11     -11.2   -11.3

  4ey6     2.40             33--574     -8.3        -11.7   -12     -11.6

  4ey8     2.60             33--574     -8.8        -11     -10.7   -11.2

  4moe     2.00             33--574     -8.6        -10.6   -10.8   -10.5

  4pqe     2.90             32--574     -8.3        -11.1   -11.1   -10.7

  5foq     2.30             32--576     -12.2       -14.5   -14.7   -13.8

  5fpq     2.40             33--574     -9.1        -11     -11.2   -11.4

  5hf5     2.15             33--574     -8.8        -10     -10.2   -10.4

  5hf6     2.30             33--574     -8.9        -10.8   -10.3   -11

  5hf8     2.80             33--574     -9.2        -11.1   -11.5   -8.9

  5hf9     2.20             33--574     -7.9        -12.6   -9.9    -12.3

  5hfa     2.20             33--574     -7.2        -9.2    -9      -9
  -------------------------------------------------------------------------

10.1371/journal.pone.0211935.t005

###### Binding affinity values of donepezil, D8, D9, and D10 docked against multiple AChE conformers generated by 25 ns MD simulation.

![](pone.0211935.t005){#pone.0211935.t005g}

  MD Conformers   Donepezil   D8      D9      D10
  --------------- ----------- ------- ------- -------
  1ns             -10.5       -13.0   -14.5   -14.0
  2ns             -10.6       -14.3   -14.2   -14.7
  3ns             -11.4       -12.4   -14.6   -11.6
  4ns             -10.1       -13     -14.3   -13.7
  5ns             -10.5       -13.9   -14.7   -10.8
  6ns             -10.8       -13.9   -14.0   -14.6
  7ns             -10.0       -13.6   -14.8   -13.8
  8ns             -10.5       -14.3   -14.9   -14.2
  9ns             -10.7       -14.1   -14.3   -14.5
  10ns            -10.8       -14.5   -14.1   -12.0
  11ns            -10.5       -13.8   -14.1   -10.6
  12ns            -10.2       -13.9   -14.0   -14.2
  13ns            -10.2       -13.0   -14.2   -13.5
  14ns            -10.4       -13.4   -14.4   -11.3
  15ns            -10.2       -10.8   -14.9   -11.1
  16ns            -10.6       -10.7   -14.3   -10.1
  17ns            -10.9       -15.1   -15.2   -15.2
  18ns            -10.4       -14.2   -14.1   -14.2
  19ns            -10.4       -13.4   -14.5   -10.8
  20ns            -9.8        -13.3   -14.1   -13.5
  21ns            -10.0       -13.1   -14.2   -13.4
  22ns            -10.5       -11.4   -14.9   -11.1
  23ns            -10.5       -13.6   -14.3   -10.8
  24ns            -10.4       -13.4   -14.1   -14.0
  25ns            -10.5       -13.6   -14     -14.1

10.1371/journal.pone.0211935.t006

###### Nonbonding interactions of the best docked complexes obtained from ensemble based docking analysis.

![](pone.0211935.t006){#pone.0211935.t006g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Conformers\      Compounds   Hydrophobic   Hydrogen Bond   Electrostatic                                                                                        
  ---------------- ----------- ------------- --------------- --------------- -------------- -------------- ---------- ------- ---------- ------- -------- ------- --
  5foq             Donepezil   Pi-Alkyl      TYR337          X               5.074          Conventional   PHE295     H...O   1.944                               

  TYR341           X           4.964                                                                                                                              

  Pi-Pi Stacked    TRP86       X1            3.844                                                                                                                

  TRP86            X1          3.851                                                                                                                              

  TRP286           X           5.086                                                                                                                              

  TRP286           X           3.890                                                                                                                              

  TYR341           X1          5.605                                                                                                                              

  Pi-Pi T-Shaped   TYR337      X             5.314                                                                                                                

  Pi-Sigma         TRP286      H...X         3.689                                                                                                                

  D8               Pi-Alkyl    TYR337        X2              5.338           Conventional   SER293         H...O      3.362                                       

  PHE338           X2          5.069                                                                                                                              

  TYR341           X2          5.108                                                                                                                              

  Pi-Pi Stacked    TRP86       X2            4.661           Pi-Donor        TRP286         H... π         4.121                                                  

  TRP86            X2          5.402                                                                                                                              

  TRP86            X2          4.397                                                                                                                              

  TRP86            X2          4.055                                                                                                                              

  TRP86            X2          4.884                                                                                                                              

  TRP286           X1          5.227                                                                                                                              

  TRP286           X1          4.048                                                                                                                              

  Pi-Pi T-Shaped   TYR337      X2            5.314                                                                                                                

  D9               Pi-Alkyl    TYR337        X2              5.421           Conventional   TYR124         H...O      2.989                                       

  PHE338           X2          5.032                                                                                                                              

  TYR341           X2          5.224                                                                                                                              

  Pi-Pi Stacked    TRP86       X2            4.651                                                                                                                

  TRP86            X2          5.426                                                                                                                              

  TRP86            X2          4.405                                                                                                                              

  TRP86            X2          4.041                                                                                                                              

  TRP86            X2          4.885                                                                                                                              

  TRP286           X1          5.233                                                                                                                              

  TRP286           X1          3.987                                                                                                                              

  D10              Pi-Alkyl    TYR337        X2              5.486           Conventional   TYR124         H...O      3.086                                       

  PHE338           X2          4.986                                                                                                                              

  SER293           H...O       3.375                                                                                                                              

  TYR341           X2          5.311                                                                                                                              

  Pi-Pi Stacked    TRP86       X2            4.663                                                                                                                

  TRP86            X2          5.419                                                                                                                              

  TRP86            X2          4.409                                                                                                                              

  TRP86            X2          4.052                                                                                                                              

  TRP86            X2          4.888                                                                                                                              

  TRP286           X1          5.260                                                                                                                              

  TRP286           X1          3.951                                                                                                                              

  17ns             Donepezil   Pi-Alkyl      PHE338          X               4.624          Conventional   TYR124     H...O   2.332                               

  Pi-Pi Stacked    TRP86       X             5.655                                                                                                                

  TRP86            X           5.717                                                                                                                              

  TRP286           X1          5.690                                                                                                                              

  TRP286           X1          4.545                                                                                                                              

  TYR337           X           4.055                                                                                                                              

  TYR341           X1          4.479                                                                                                                              

  D8               Pi-Alkyl    PHE338        X2              4.992           Conventional   TYR124         H...O      2.251   Pi-Anion   ASP74   O...X2   4.64    

  TYR72            H...O       2.026                                                                                                                              

  TYR72            H...O       3.065                                                                                                                              

  Pi-Pi T-Shaped   TRP86       X2            3.738           Pi-Donor        TRP286         H...π          3.879                                                  

  TRP86            X2          5.618                                                                                                                              

  TRP86            X2          4.092                                                                                                                              

  TRP86            X2          4.524                                                                                                                              

  TRP86            X2          5.860                                                                                                                              

  TRP86            X2          4.608                                                                                                                              

  TRP286           X1          5.163                                                                                                                              

  TRP286           X1          4.244                                                                                                                              

  TYR337           X2          3.981                                                                                                                              

  TYR337           X2          5.075                                                                                                                              

  TYR341           X1          4.700                                                                                                                              

  D9               Pi-Alkyl    TYR124        X2              5.476           Conventional   TYR124         H...O      2.539   Pi-Anion   ASP74   O...X2   4.467   

  PHE338           X2          5.257                                                                                                                              

  Pi-Pi Stacked    TRP86       X2            3.713                                                                                                                

  TRP86            X2          5.660                                                                                                                              

  TRP86            X2          4.109                                                                                                                              

  TRP86            X2          4.343                                                                                                                              

  TRP86            X2          5.805                                                                                                                              

  TRP86            X2          4.484                                                                                                                              

  TRP286           X1          5.144                                                                                                                              

  TRP286           X1          4.408                                                                                                                              

  TYR337           X2          3.991                                                                                                                              

  TYR337           X2          5.086                                                                                                                              

  TYR341           X1          4.591                                                                                                                              

  D10              Pi-Alkyl    PHE338        X2              5.208           Conventional   PHE295         C--H...O   2.882   Pi-Anion   ASP74   O...X2   4.500   

  SER293           C--H...O    2.839                                                                                                                              

  SER293           C--H...O    3.323                                                                                                                              

  VAL294           X2          5.317                                                                                                                              

  Pi-Pi Stacked    TRP86       X2            3.869                                                                                                                

  TRP86            X2          5.260                                                                                                                              

  TRP86            X2          3.912                                                                                                                              

  TRP86            X2          4.645                                                                                                                              

  TRP86            X2          5.466                                                                                                                              

  TRP86            X2          4.424                                                                                                                              

  TYR337           X1          4.165                                                                                                                              

  TYR337           X1          5.382                                                                                                                              

  Pi-Sigma         TYR124      H...X2        3.391                                                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

Here X, X1, X2 indicates that, X = Benzyl-4-piperidyl, X1 = 2,3-dihydro-1H-inden-1-one, X2 = Anthracen-9-ylmethyl-4-piperidyl

ADME/T analysis {#sec014}
---------------

In order to analyze whether the modified compounds produce any toxicity or altered pharmacokinetic profile, the admetSAR server was utilized. Different pharmacokinetic and pharmacodynamic parameters such as human intestinal absorption, \[[@pone.0211935.ref045]\] blood--brain barrier penetration, cytochrome P450 inhibition, \[[@pone.0211935.ref046]\] human ether-a-go-go-related genes inhibition, acute oral Toxicity, and rat acute toxicity were considered. The results are summarized in **[Table 7](#pone.0211935.t007){ref-type="table"}**. As shown in **[Table 7](#pone.0211935.t007){ref-type="table"}**, all compounds revealed a positive value (value above the prescribed threshold suggesting good permeability) with high probabilities, in case of blood-brain barrier and human intestinal absorption. Furthermore, modifications of donepezil resulted in a non--inhibitor of P-glycoprotein. The analysis displayed that D2, D4, D5, D6 and D9 were potential compounds of the human ether-a-go-go-related gene. All compounds showed a similar oral toxicity profile, while D9 and D2 indicated the highest LD~50~ value in rat acute toxicity, demonstrating non-toxic with respect to parent donepezil.

10.1371/journal.pone.0211935.t007

###### Selected pharmacokinetic parameters of donepezil and its designed analogues.

![](pone.0211935.t007){#pone.0211935.t007g}

  Parameters                          Donepezil   D1       D2       D3       D4       D5       D6       D7       D8       D9       D10
  ----------------------------------- ----------- -------- -------- -------- -------- -------- -------- -------- -------- -------- ------
  Blood-Brain Barrier                 \+          \+       \+       \+       \+       \+       \+       \+       \+       \+       \+
  (0.99)                              (0.93)      (0.93)   (0.90)   (0.90)   (0.89)   (0.91)   (0.93)   (0.93)   (0.93)   (0.90)   
  Human Intestinal Absorption         \+          \+       \+       \+       \+       \+       \+       \+       \+       \+       \+
  (0.99)                              (0.66)      (0.79)   (0.79)   (0.72)   (0.58)   (0.60)   (0.66)   (0.66)   (0.79)   (0.79)   
  P-glycoprotein Inhibitor            I           NI       NI       NI       NI       NI       NI       NI       NI       NI       NI
  (0.69)                              (0.90)      (0.83)   (0.82)   (0.76)   (0.84)   (0.85)   (0.90)   (0.90)   (0.83)   (0.82)   
  CYP450 2C9 Inhibitor                NI          NI       NI       NI       NI       NI       NI       NI       NI       NI       NI
  (0.88)                              (0.83)      (0.80)   (0.80)   (0.79)   (0.79)   (0.78)   (0.83)   (0.83)   (0.80)   (0.80)   
  Human Ether-a-go-go-Related Gene    I           NI       I        NI       I        I        I        NI       NI       I        NI
  (0.68)                              (0.61)      (0.58)   (0.50)   (0.51)   (0.50)   (0.56)   (0.61)   (0.61)   (0.58)   (0.50)   
  Acute Oral Toxicity                 III         III      III      III      III      III      III      III      III      III      III
  (0.56)                              (0.55)      (0.55)   (0.54)   (0.54)   (0.54)   (0.55)   (0.55)   (0.55)   (0.55)   (0.54)   
  Rat Acute Toxicity (LD50, mol/kg)   2.70        2.59     2.72     2.71     2.69     2.69     2.71     2.59     2.59     2.72     2.71

\+ = Positive, I = Inhibitor, NI = Non-Inhibitor, III = Category III includes compounds with LD50 values greater than 500mg/kg but less than 5000mg/kg.

In addition, ADME/T prediction of D9-Fe, D9-Co, D9-Zn, and D9-Ni was performed and compared with the D9-Cu analogue. D9 with different metals revealed the same values as D9-Cu. An exception, D9-Zn, showed a negative value in human oral absorption. These results have been summarized in [S2 Table](#pone.0211935.s002){ref-type="supplementary-material"}. A published review by Mjos *et al*. 2014 \[[@pone.0211935.ref047]\] discussed the importance of metal based drugs in the diagnosis of disease and enlisted a number of metal-based drug names which are already approved by the FDA and which have undergone clinical trials (shown in **[S3 Table](#pone.0211935.s003){ref-type="supplementary-material"}**). From **[S3 Table](#pone.0211935.s003){ref-type="supplementary-material"},** we also predicted the pharmacokinetic parameters and toxicity of some drugs (data is shown in **[S4 Table](#pone.0211935.s004){ref-type="supplementary-material"}**).

Conclusion {#sec015}
==========

In summary, the present study revealed some novel metal directed AChE inhibitors, developed by modifying a known inhibitor, donepezil. Modification with Cu, along with substitution using aromatic rings and halogens increased the dipole moment and π-π interaction capacity of the designed compounds. Furthermore, these modified compounds were more reactive than donepezil, as they showed lower HOMO‒LUMO gaps. Molecular interaction analyses of docking simulations revealed similar binding conformations of all compounds at the active site and suggested D9 as a potent inhibitor, which can equally interact with both the CAS (Trp86) and PAS sites (Trp286) of AChE. The structural analysis with subsequent MD simulations demonstrated that D9 formed a stable conformation by creating hydrophobic and aromatic interactions with the active site residues such as Tyr337, Phe295, Tyr72, and Phe338. In addition, π-π stacking interactions with the residues of Trp86, Tyr337, Tyr341, Tyr124, and Trp286 may play a major role for strong drug binding and activity, according to ensemble based docking. Moreover, ADME/T analyses suggested that modified analogues were less toxic and have improved pharmacokinetic profiles than the parent drug. These results further confirmed the ability of Cu and other metal-directed analogues to bind simultaneously to the active sites of AChE and support them as potential candidates for the future treatment of Alzheimer's disease.
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###### Most stable optimized structures of D9-Fe, D9-Co, D9-Zn and D9-Ni along with D9.

(TIF)
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Click here for additional data file.

###### 

Predicted pose from docking analysis showed the binding orientation map of important amino acids for **a) D9-Fe, b) D9-Co, c) D9-Zn and d) D9-Ni**, showing hydrogen bond interaction (green color), including π--π stacking (pink color).
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